fbpx
QQQ
-2.49
316.84
-0.79%
DIA
-2.00
312.11
-0.64%
SPY
-2.91
381.49
-0.77%
TLT
+ 0.60
150.62
+ 0.4%
GLD
-2.07
175.30
-1.19%

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

November 9, 2020 6:27 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of November 2nd – 8th, 2020.

Without further ado, let’s get started.

Yahoo Finance readers, please click here to view the full article.

10. Cannabis Stocks Go Bonkers as 2020 U.S. Election Brings Massive Green Wave

The 2020 U.S. Election Saw 5 New States Approve Marijuana Legalization Measures, Which New Frontier Data Expects Could Grow the Size of the Cannabis Industry By an Estimated $9 Billion

Despite some lingering uncertainty surrounding the race for the Presidency between President Donald Trump and former Vice President Joe Biden, cannabis investors arguably walked away from this year’s election as the biggest winners, as evidenced by U.S. and Canadian Pot Stocks’ week of blistering gains.

READ FULL CANNABIS ELECTION ARTICLE

9. This Psychedelic Stock Was a Winner on Election Night

Voters in Oregon Approved a Ballot Measure That Legalizes a Treatment This Newly Public Company Has in Clinical Trials

Biotech startup Compass Pathways (NASDAQ:CMPS) got good news in the U.S. election last night when Oregon became the first state in the nation to legalize the use of psilocybin — the active ingredient in Psychedelic mushrooms — as a therapeutic treatment in mental healthcare.

READ FULL COMPASS PATHWAYS ARTICLE

8. Aphria’s Deal to Buy SweetWater Brewing is a Good One, Says Haywood

Haywood Capital Markets Analyst Neal Gilmer Likes the New Craft Brewer Acquisition in the United States By Cannabis Company Aphria

In an update to clients, the analyst stated that the deal adds diversification to Aphria’s NYSE: APHA) lineup ahead of the potential legalization of cannabis in the US. The deal is valued at approximately $300 million including $250 million in cash and the rest in stock, along with up to $66 million in additional cash earnouts up to 2023.

READ FULL APHRIA ARTICLE

7. Havn Life Sciences CEO on Decriminalization of Psychedelics in Oregon and Washington D.C.

DC’s Initiative 81 Passed, Decriminalizing a Wide Range of Psychedelics and Oregonians Voted in Favor of Measure 109, Allowing Patients 21-and-Over to Buy, Possess, and Consume Psychedelic Drugs at “Psilocybin Service Centers”

Havn Life Sciences (CSE:HAVN) CEO Tim Moore joined The Dales Report to discuss the recent news last week concerning the U.S. Election and the decriminalization of Psychedelic drugs in both Oregon and Washington D.C.

READ FULL HAVN LIFE ARTICLE

6. Aurora Cannabis’ Revenues Fall 6% To $67.8 Million In Q1 2021, Net Loss Hits $109.5 Million

Net Revenue Fell on a Quarterly Basis From $72.1M to $67.8M, a Function of Both Discontinued Operations in Aurora Hemp Europe and Aurora Larssen Projects, as Well as Declining Cannabis Sales

Whereas Canopy Growth (NYSE:CGC) posted revenue growth of 22.5% this morning on a quarter over quarter basis, Aurora Cannabis (NYSE:ACB)  continued to give up its lead, with Aurora revenues declining 5.96% on a quarterly basis. Aurora’s net revenues hit $67.8 million, while the net loss amounted to $109.5 million.

READ FULL AURORA CANNABIS ARTICLE

5. Field Trip Health Prepares to Enter Oregon Market following the Passage of Measure 109 in Oregon, Creating the First Legal Market for Psilocybin Services

Field Trip is Rolling Out Field Trip Health Centers for the Delivery of Psychedelic Therapies, is Positioned Be a Leader in the Emerging Psychedelic Renaissance

Field Trip Health (OTC:FTRPF), one of the leaders in the development and delivery of Psychedelic therapies, announced today that it is in the advanced stages of identifying potential sites for Field Trip Health centers to treat people in Oregon with Psilocybin therapies following the passage of Measure 109.

READ FULL FIELD TRIP ARTICLE

4. Canopy Growth’s Net Revenue Climbs 22.5% to $135.3 Million in Q2, Records Loss of $96.6 Million

The Company’s Revenue Growth Came Largely From Canadian Recreational Net Revenue, Which Rose From $44.2 Million to $60.9 Million During the Quarter

Canopy Growth (NYSE:CGC) reported its second-quarter 2021 Earnings, reporting net revenues of $135.3 million along with a net loss of $96.6 million for the period ended September 30, 2020. Revenues were up significantly on a quarter over quarter basis, with growth amounting to 22.5%.

READ FULL CANOPY GROWTH ARTICLE

3. How a Decriminalization Vote is Making Psychedelics Investors a Lot of Money

And So it Begins. On Election Night, Washington, D.C., and Oregon Voted to Decriminalize Psychedelics

More than a dozen publicly traded Psychedelic Stocks, and literally hundreds of millions of dollars now flowing into Psychedelics startups. I’ve personally done quite well with some of these, particularly MindMed (OTCQB:MMEDF), which has already more than doubled my initial investment. And honestly, this market is only now starting to really heat up.

READ FULL PSYCHEDELICS INVESTORS

2. Curaleaf Completes Purchase of ATG’s Massachusetts Facilities, Sells Maryland Assets

The Acquisition Agreement, Confirmed Thursday, Was First Signed Back in August of 2018

Cannabis company Curaleaf (OTCQX:CURLF)  finalized the purchase transaction of Alternative Therapies Group’s licensed cultivation and processing facility in Amesbury, Massachusetts.

READ FULL CURALEAF ARTICLE

1. MindMed Announces the Completion of Phase 1 Study Measuring Dosing Effects of LSD

Data to Support MindMed’s Project Lucy in Preparing Phase 2b Trial for Anxiety Disorders

MindMed (OTCQB:MMEDF) the leading Psychedelic medicine biotech company in partnership with University Hospital Basel’s Liechti Lab announces the completion and publication of a Phase 1 study on the acute dose dependent effects of LSD. The completed Phase 1 study will help MindMed in dose-finding and the planning of future Phase 2 clinical trials of LSD in patients with anxiety disorders and other medical conditions.

READ FULL MINDMED ARTICLE

Photo by Matthew Brodeur on Unsplash


Related Articles

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of January 4th – 10th, 2021. Without further ado, let’s get started. read more

Psyched: Compass Launches Center Of Excellence, Entheon Purchases HaluGen, Atai Buys Majority Stake In Recognify

Compass Launches Center Of Excellence Compass Pathways (NASDAQ: CMPS) officially launched the Centre of Excellence, in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland. read more

The Week In Cannabis: Stocks Spike By Double Digits On Earnings, Strong Sales, Financings

Cannabis stocks widely outperformed the markets after a slew of financing deals and strong earnings reports. read more

Cannabis Stock Gainers And Losers From January 15, 2021

GAINERS: Next Green Wave Holdings (OTCQX: NXGWF) shares closed up 17.73% at $0.51 read more

Cannabis Stock Gainers And Losers From January 14, 2021

GAINERS: Flower One Hldgs (OTCQX: FLOOF) shares closed up 37.3% at $0.21 read more